ABT - Abbott Laboratories
| Previous Close | 54.63 |
| Open | 54.59 |
| Bid | 54.95 x 3100 |
| Ask | 55.72 x 100 |
| Day's Range | 54.40 - 55.23 |
| 52 Week Range | 37.38 - 55.43 |
| Volume | 5,432,973 |
| Avg. Volume | 5,526,758 |
| Market Cap | 95.66B |
| Beta | 1.65 |
| PE Ratio (TTM) | 77.11 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.06 (1.94%) |
| Ex-Dividend Date | 2017-10-12 |
| 1y Target Est | N/A |
- Yahoo Finance•13 hours ago
Beige Book, AmEx, and eBay — What you need to know on Wednesday
The Federal Reserve, American Express, and eBay will be the big stories on Wednesday as tax reform continues to dominate the Washington-related headlines.
- Zacks•22 hours ago
Phibro Animal Banks on Diverse Portfolio, Competition Rife
Phibro Animal (PAHC) is consistently trying to expand its product portfolio to counter the tough competition in the animal health space.
- Zacks•22 hours ago
Henry Schein (HSIC) Inks Distribution Agreement with Terason
Henry Schein's (HSIC) distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen is likely to boost its global Medical segment business.
- Zacks•23 hours ago
The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare
The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare
- Zacks•2 days ago
Top Research Reports for AbbVie, American Express & Abbott
Top Research Reports for AbbVie, American Express & Abbott
- Zacks•2 days ago
Here's Why You Should Buy Thermo Fisher Scientific (TMO) Now
Based on a wide range of fundamental factors, Thermo Fisher (TMO) is a great pick for now.
- Zacks•2 days ago
Here's Why Investors Should Buy Integra LifeSciences Now
The market is upbeat about Integra LifeSciences' (IART) latest developments that include product launches and strategic buyouts.
- Zacks•2 days ago
TransEnterix Senhance Surgical Robotic System Wins FDA Nod
TransEnterix (TRXC) works on expanding in robotic surgery consistently.
- Zacks•5 days ago
Abbott Banks on FDA Approvals and Buyouts, Competition Rife
The market is upbeat about Abbott's (ABT) latest initiatives.
- Market Realist•5 days ago
Assessing Abbott’s 3Q17 Expectations by Segment
In 3Q17, the Established Pharmaceuticals segment of Abbott Laboratories is expected to report high double-digit operational sales growth.
- Market Realist•6 days ago
What to Expect from Abbott Laboratories’ 3Q17 Earnings
The 3Q17 EPS estimate for Abbott Laboratories is $0.65. The company has provided an EPS guidance range of $0.64–$0.66 for 3Q17.
- Market Realist•6 days ago
Inside Abbott’s 3Q17 Revenue Expectations: Hit or Miss?
Analysts expect Abbott Laboratories to report 3Q17 revenues of ~$6.7 billion, representing a YoY (year-over-year) growth of ~26.7%.
- Zacks•6 days ago
DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay
DENTSPLY SIRONA's (XRAY) renewed distribution deal will aid the company to gain market traction. However, forex woes remain a concern.
- Market Realist•6 days ago
Abbott’s Analyst Recommendations ahead of Its 3Q17 Results
On October 18, 2017, Abbott Laboratories will release its 3Q17 earnings results. Abbott stock was trading at its 52-week high of $55.4 on October 10.
